五氨基水杨酸：老药再评价的新进展。
Five-aminosalicylic Acid: an update for the reappraisal of an old drug.
机构信息
Unit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences "Luigi Sacco", University Hospital "Luigi Sacco", Università di Milano, 20157 Milan, Italy.
Unit of General Surgery, Department of Biomedical and Clinical Sciences "Luigi Sacco", University Hospital "Luigi Sacco", Università di Milano, 20157 Milan, Italy.
出版信息
Gastroenterol Res Pract. 2015;2015:456895. doi: 10.1155/2015/456895. Epub 2015 Jan 21.
Abstract
Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn's disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.
摘要
炎症性肠病（IBD）包括几种具有慢性或复发性免疫反应和胃肠道炎症的疾病，其中溃疡性结肠炎和克罗恩病是最常见的形式。这种疾病的患病率很高，其病因尚不清楚。5-氨基水杨酸（5-ASA）及其衍生物是最早被批准用于治疗 IBD 的药物之一。在这篇综述中，我们重新评估了 5-ASA 的作用机制、安全性和疗效，我们认为它是一种有价值的药物，可以与其他免疫调节剂一起作为治疗选择，为个体化治疗提供更多的选择。
相似文献
1
Five-aminosalicylic Acid: an update for the reappraisal of an old drug.五氨基水杨酸：老药再评价的新进展。
Gastroenterol Res Pract. 2015;2015:456895. doi: 10.1155/2015/456895. Epub 2015 Jan 21.
2
3
Inflammatory bowel disease. Part II: Clinical and therapeutic aspects.炎症性肠病。第二部分：临床与治疗方面。
Dis Mon. 1991 Nov;37(11):669-746. doi: 10.1016/s0011-5029(05)80013-6.
4
Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.炎症性肠病患者幽门螺杆菌感染率的评估。
Eur J Gastroenterol Hepatol. 2000 Apr;12(4):439-43. doi: 10.1097/00042737-200012040-00012.
5
Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.比较在开始抗肿瘤坏死因子-α治疗后继续/停止 5-氨基水杨酸治疗对炎症性肠病患者结局的影响。
Int J Colorectal Dis. 2019 Oct;34(10):1713-1721. doi: 10.1007/s00384-019-03368-1. Epub 2019 Aug 31.
6
Inflammatory bowel disease. Part I: Nature and pathogenesis.炎症性肠病。第一部分：性质与发病机制。
Dis Mon. 1991 Oct;37(10):605-66. doi: 10.1016/0011-5029(91)90024-6.
7
A comprehensive review and update on Crohn's disease.克罗恩病的全面综述与更新
Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001. Epub 2017 Aug 18.
8
Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model.胃肠道中抗炎药物的位点特异性递送：一种体外释放模型。
J Pharm Pharmacol. 2005 Jun;57(6):709-19. doi: 10.1211/0022357056172.
9
5-Aminosalicylic acid, a specific drug for ulcerative colitis.5-氨基水杨酸，一种治疗溃疡性结肠炎的特效药物。
Scand J Gastroenterol. 2015 Aug;50(8):933-41. doi: 10.3109/00365521.2015.1018937. Epub 2015 Mar 2.
10
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病：英夫利昔单抗和硫唑嘌呤治疗成功
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
引用本文的文献
1
[Efficient treatment of mild Crohn's disease and mild ulcerative colitis].[轻度克罗恩病和轻度溃疡性结肠炎的有效治疗]
Inn Med (Heidelb). 2025 Jan;66(1):15-21. doi: 10.1007/s00108-024-01840-x. Epub 2024 Dec 23.
2
Oral colon-targeted pH-responsive polymeric nanoparticles loading naringin for enhanced ulcerative colitis therapy.口服结肠靶向 pH 响应型载柚皮苷聚合物纳米粒增强溃疡性结肠炎治疗。
J Transl Med. 2024 Sep 30;22(1):878. doi: 10.1186/s12967-024-05662-1.
3
Oral delivery of pH-sensitive nanoparticles loaded Celastrol targeting the inflammatory colons to treat ulcerative colitis.口服负载雷公藤红素的pH敏感纳米颗粒靶向炎症性结肠以治疗溃疡性结肠炎。
J Tissue Eng. 2024 Aug 10;15:20417314241265892. doi: 10.1177/20417314241265892. eCollection 2024 Jan-Dec.
4
The aminosalicylate - folate connection.氨基水杨酸盐-叶酸的关联。
Drug Metab Rev. 2024 Feb;56(1):80-96. doi: 10.1080/03602532.2024.2303507. Epub 2024 Jan 17.
5
Gut Microbiome-Wide Search for Bacterial Azoreductases Reveals Potentially Uncharacterized Azoreductases Encoded in the Human Gut Microbiome.肠道微生物组范围内对细菌偶氮还原酶的搜索揭示了人类肠道微生物组中编码的潜在未表征的偶氮还原酶。
Drug Metab Dispos. 2023 Jan;51(1):142-153. doi: 10.1124/dmd.122.000898. Epub 2022 Sep 18.
6
Genome Mining and Metabolomics Unveil Pseudonochelin: A Siderophore Containing 5-Aminosalicylate from a Marine-Derived sp. Bacterium.基因组挖掘和代谢组学揭示假诺卡霉素：一种来源于海洋衍生 sp. 细菌的含有 5-氨基水杨酸的铁载体。
Org Lett. 2022 Jun 10;24(22):3998-4002. doi: 10.1021/acs.orglett.2c01408. Epub 2022 Jun 1.
7
Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence.COVID-19 大流行对炎症性肠病患者的影响：当前证据综述。
World J Gastroenterol. 2021 Jul 7;27(25):3748-3761. doi: 10.3748/wjg.v27.i25.3748.
8
Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-ɣ): Molecular Effects and Its Importance as a Novel Therapeutic Target for Cerebral Ischemic Injury.过氧化物酶体增殖物激活受体-γ（PPAR-ɣ）：分子作用及其作为脑缺血损伤新型治疗靶点的重要性。
Neurochem Res. 2021 Nov;46(11):2800-2831. doi: 10.1007/s11064-021-03402-1. Epub 2021 Jul 20.
9
Treatments of inflammatory bowel disease toward personalized medicine.炎症性肠病的个体化医学治疗。
Arch Pharm Res. 2021 Mar;44(3):293-309. doi: 10.1007/s12272-021-01318-6. Epub 2021 Mar 24.
10
Artificial Neural Network (ANN) Approach to Predict an Optimized pH-Dependent Mesalamine Matrix Tablet.人工神经网络（ANN）方法预测优化的 pH 依赖性美沙拉嗪基质片剂。
Drug Des Devel Ther. 2020 Jun 22;14:2435-2448. doi: 10.2147/DDDT.S244016. eCollection 2020.
本文引用的文献
1
High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis.高剂量和低剂量口服缓释美沙拉嗪用于轻度至中度活动性溃疡性结肠炎儿童
J Pediatr Gastroenterol Nutr. 2014 Dec;59(6):767-72. doi: 10.1097/MPG.0000000000000530.
2
The history of genetics in inflammatory bowel disease.炎症性肠病的遗传学历史。
Ann Gastroenterol. 2014;27(4):294-303.
3
Decade in review-IBD: IBD-genes, bacteria and new therapeutic strategies.十年回顾——炎症性肠病：炎症性肠病基因、细菌与新治疗策略
Nat Rev Gastroenterol Hepatol. 2014 Nov;11(11):652-4. doi: 10.1038/nrgastro.2014.170. Epub 2014 Oct 14.
4
Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.美沙拉嗪颗粒剂每日一次治疗活动期溃疡性结肠炎的长期疗效和安全性
Clin Exp Gastroenterol. 2014 Sep 23;7:369-83. doi: 10.2147/CEG.S35691. eCollection 2014.
5
Current issues in inflammatory bowel disease neoplasia.炎症性肠病肿瘤学的当前问题。
Histopathology. 2015 Jan;66(1):37-48. doi: 10.1111/his.12565.
6
Early phase of acute pancreatitis: Assessment and management.急性胰腺炎的早期阶段：评估与管理。
World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):158-68. doi: 10.4291/wjgp.v5.i3.158.
7
Learning from myocarditis: mimicry, chaos and black holes.从心肌炎中学习：模仿、混沌与黑洞。
F1000Prime Rep. 2014 May 6;6:25. doi: 10.12703/P6-25. eCollection 2014.
8
Management of disconnected left pancreatic remnant after necrotizing pancreatitis.坏死性胰腺炎后游离左胰腺残端的处理
Am Surg. 2014 May;80(5):E137-8.
9
Risk factors for post-ERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years.经内镜逆行胰胆管造影术后胰腺炎的危险因素：过去 10 年大样本量临床试验的系统评价。
Eur J Med Res. 2014 May 15;19(1):26. doi: 10.1186/2047-783X-19-26.
10
Recurrent acute pancreatitis: an approach to diagnosis and management.复发性急性胰腺炎：诊断与管理方法
Trop Gastroenterol. 2013 Jul-Sep;34(3):123-35. doi: 10.7869/tg.116.
Zotero 插件